Your browser doesn't support javascript.
loading
Total Ankle Replacement Versus Arthrodesis for End-Stage Ankle Osteoarthritis: A Randomized Controlled Trial.
Goldberg, Andrew J; Chowdhury, Kashfia; Bordea, Ekaterina; Hauptmannova, Iva; Blackstone, James; Brooking, Deirdre; Deane, Elizabeth L; Bendall, Stephen; Bing, Andrew; Blundell, Chris; Dhar, Sunil; Molloy, Andrew; Milner, Steve; Karski, Mike; Hepple, Steve; Siddique, Malik; Loveday, David T; Mishra, Viren; Cooke, Paul; Halliwell, Paul; Townshend, David; Skene, Simon S; Doré, Caroline J; Brown, Rick; Butler, Michael; Chadwick, Carolyn; Clough, Tim; Cullen, Nick; Davies, Mark; Davies, Howard; Harries, Bill; Khoo, Michael; Makwana, Nilesh; Murty, An; Najefi, Ali; O'Donnell, Paul; Raglan, Martin; Thomas, Rhys; Torres, Paulo; Welck, Matthew; Winson, Ian; Zaidi, Razi.
Afiliação
  • Goldberg AJ; UCL Institute of Orthopaedics & Musculoskeletal Science, Division of Surgery, Royal Free Hospital, MSK Lab, Imperial College London, Sir Michael Uren Hub Imperial College London White City Campus, London, and Department of Research & Innovation, Royal National Orthopaedic Hospital (RNOH), Br
  • Chowdhury K; UCL Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom (K.C., E.B., J.B., E.L.D., C.J.D.).
  • Bordea E; UCL Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom (K.C., E.B., J.B., E.L.D., C.J.D.).
  • Hauptmannova I; Department of Research & Innovation, Royal National Orthopaedic Hospital (RNOH), Brockley Hill, Stanmore, Middlesex, United Kingdom (I.H., D.B.).
  • Blackstone J; UCL Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom (K.C., E.B., J.B., E.L.D., C.J.D.).
  • Brooking D; Department of Research & Innovation, Royal National Orthopaedic Hospital (RNOH), Brockley Hill, Stanmore, Middlesex, United Kingdom (I.H., D.B.).
  • Deane EL; UCL Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom (K.C., E.B., J.B., E.L.D., C.J.D.).
  • Bendall S; University Hospitals Sussex NHS Foundation Trust, Haywards Heath, United Kingdom (S.B.).
  • Bing A; The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust, Oswestry, Shropshire, United Kingdom (A.B.).
  • Blundell C; Sheffield Teaching Hospitals NHS Trust, Northern General Hospital, Sheffield, United Kingdom (C.B.).
  • Dhar S; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom (S.D.).
  • Molloy A; Liverpool University Hospitals NHS Foundation Trust, Fazakerley, Liverpool, United Kingdom (A.M.).
  • Milner S; University Hospitals of Derby and Burton NHS Foundation Trust, Derby, United Kingdom (S.M.).
  • Karski M; Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, Lancashire, United Kingdom (M.K.).
  • Hepple S; North Bristol NHS Trust, Bristol, United Kingdom (S.H.).
  • Siddique M; Newcastle Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, United Kingdom (M.S.).
  • Loveday DT; Norfolk and Norwich University Hospitals NHS Foundation Trust, Norfolk and Norwich University Hospital, Norwich, United Kingdom (D.T.L.).
  • Mishra V; Hull University Teaching Hospitals NHS Trust, Hull Royal Infirmary, Hull, United Kingdom (V.M.).
  • Cooke P; Oxford University Hospitals NHS Trust, Nuffield Orthopaedic Centre, Oxford, United Kingdom (P.C.).
  • Halliwell P; Royal Surrey NHS Foundation Trust, Guildford, Surrey, United Kingdom (P.H.).
  • Townshend D; Northumbria Healthcare NHS Foundation Trust, Tyne and Wear, North Shields, United Kingdom (D.T.).
  • Skene SS; Surrey Clinical Trials Unit, University of Surrey, Guildford, Surrey, United Kingdom (S.S.S.).
  • Doré CJ; UCL Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom (K.C., E.B., J.B., E.L.D., C.J.D.).
Ann Intern Med ; 175(12): 1648-1657, 2022 12.
Article em En | MEDLINE | ID: mdl-36375147
BACKGROUND: End-stage ankle osteoarthritis causes severe pain and disability. There are no randomized trials comparing the 2 main surgical treatments: total ankle replacement (TAR) and ankle fusion (AF). OBJECTIVE: To determine which treatment is superior in terms of clinical scores and adverse events. DESIGN: A multicenter, parallel-group, open-label randomized trial. (ISRCTN registry number: 60672307). SETTING: 17 National Health Service trusts across the United Kingdom. PATIENTS: Patients with end-stage ankle osteoarthritis, aged 50 to 85 years, and suitable for either procedure. INTERVENTION: Patients were randomly assigned to TAR or AF surgical treatment. MEASUREMENTS: The primary outcome was change in Manchester-Oxford Foot Questionnaire walking/standing (MOXFQ-W/S) domain scores between baseline and 52 weeks after surgery. No blinding was possible. RESULTS: Between 6 March 2015 and 10 January 2019, a total of 303 patients were randomly assigned; mean age was 68 years, and 71% were men. Twenty-one patients withdrew before surgery, and 281 clinical scores were analyzed. At 52 weeks, the mean MOXFQ-W/S scores improved for both groups. The adjusted difference in the change in MOXFQ-W/S scores from baseline was -5.6 (95% CI, -12.5 to 1.4), showing that TAR improved more than AF, but the difference was not considered clinically or statistically significant. The number of adverse events was similar between groups (109 vs. 104), but there were more wound healing issues in the TAR group and more thromboembolic events and nonunion in the AF group. The symptomatic nonunion rate for AF was 7%. A post hoc analysis suggested superiority of fixed-bearing TAR over AF (-11.1 [CI, -19.3 to -2.9]). LIMITATION: Only 52-week data; pragmatic design creates heterogeneity of implants and surgical techniques. CONCLUSION: Both TAR and AF improve MOXFQ-W/S and had similar clinical scores and number of harms. Total ankle replacement had greater wound healing complications and nerve injuries, whereas AF had greater thromboembolism and nonunion, with a symptomatic nonunion rate of 7%. PRIMARY FUNDING SOURCE: National Institute for Health and Care Research Heath Technology Assessment Programme.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteoartrite / Artroplastia de Substituição do Tornozelo Tipo de estudo: Clinical_trials / Health_technology_assessment Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteoartrite / Artroplastia de Substituição do Tornozelo Tipo de estudo: Clinical_trials / Health_technology_assessment Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article